RT Journal Article
SR Electronic
T1 Serum DHEA-S Is a Predictive Parameter of Abiraterone Acetate in Patients with Castration-resistant Prostate Cancer
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 5929
OP 5935
DO 10.21873/anticanres.12938
VO 38
IS 10
A1 KOTARO SUZUKI
A1 MARIKO SAKAMOTO
A1 TOMOAKI TERAKAWA
A1 JUNYA FURUKAWA
A1 KENICHI HARADA
A1 NOBUYUKI HINATA
A1 YUZO NAKANO
A1 MASATO FUJISAWA
YR 2018
UL http://ar.iiarjournals.org/content/38/10/5929.abstract
AB Background/Aim: There is no definitive biomarker that predicts the effectiveness of abiraterone acetate. The objective of this study was to investigate whether dehydroepiandrosterone sulfate (DHEA-S) predicts the effectiveness of abiraterone acetate. Materials and Methods: This study included a total of 28 consecutive patients. The optimal cutoff value of DHEA-S for predicting the PSA response was calculated by receiver operating characteristic (ROC) analysis. The Cox proportional hazards model was performed to determine the predictive factors for the susceptibility to abiraterone acetate. Results: Serum DHEA-S at baseline intercorrelated with the PSA response (correlation coefficient: −0.516). The optimal cutoff value of serum DHEA-S at baseline was 47.4 ug/dl in predicting >50% PSA decline. Serum PSA and serum DHEA-S at baseline were identified as significant factors for predicting PSA progression-free survival (p=0.010 and p=0.003, respectively). Conclusion: Serum DHEA-S at baseline may be a biomarker for predicting the prognosis of CRPC patients treated with abiraterone acetate.